Completion of cash acquisition of licenced cord blood bank expanding CytoMed's strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd

SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ('CytoMed” or the 'Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including blood and solid cancers has obtained full approval for its first-in-human Phase I clinical trial ('ANGELICA Trial”) using its patented allogeneic chimeric antigen receptor T cell ('CAR-T cell”) against several blood and solid tumors in collaboration with the National University Hospital ('NUH”) of Singapore. The ANGELICA Trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council ('NMRC”) Office, and MOH Holdings Pte Ltd under the NMRC Clinical Trial Grant Industry Collaborative Trials (CTG-ICT) scheme (MOH-001646). Grant details are confidential.